381 related articles for article (PubMed ID: 29110620)
1. Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis.
Sharma A; Jain K; Flora SJS
Med Chem; 2018; 14(3):212-224. PubMed ID: 29110620
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
Hudson SA; McLean KJ; Munro AW; Abell C
Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
[TBL] [Abstract][Full Text] [Related]
7.
Nunes JES; Duque MA; de Freitas TF; Galina L; Timmers LFSM; Bizarro CV; Machado P; Basso LA; Ducati RG
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168746
[TBL] [Abstract][Full Text] [Related]
8. Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.
Evans JC; Mizrahi V
Curr Opin Microbiol; 2018 Oct; 45():39-46. PubMed ID: 29482115
[TBL] [Abstract][Full Text] [Related]
9. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis and its Treatment: An Overview.
Bansal R; Sharma D; Singh R
Mini Rev Med Chem; 2018; 18(1):58-71. PubMed ID: 27553018
[TBL] [Abstract][Full Text] [Related]
11. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
John SF; Aniemeke E; Ha NP; Chong CR; Gu P; Zhou J; Zhang Y; Graviss EA; Liu JO; Olaleye OA
Tuberculosis (Edinb); 2016 Dec; 101S():S73-S77. PubMed ID: 27856197
[TBL] [Abstract][Full Text] [Related]
12. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
Sharma A; Khuller GK; Sharma S
Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
Saxena AK; Singh A
Curr Top Med Chem; 2019; 19(5):337-355. PubMed ID: 30806318
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.
Mascarello A; Chiaradia-Delatorre LD; Mori M; Terenzi H; Botta B
Curr Pharm Des; 2016; 22(12):1561-9. PubMed ID: 26759082
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
17. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
18. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development.
Moraes GL; Gomes GC; Monteiro de Sousa PR; Alves CN; Govender T; Kruger HG; Maguire GE; Lamichhane G; Lameira J
Tuberculosis (Edinb); 2015 Mar; 95(2):95-111. PubMed ID: 25701501
[TBL] [Abstract][Full Text] [Related]
20. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]